	Subt. Form PT	RMATION	DISCLO	SURE	Docket Number 47508-556 (HYZ-069CN2)	Application Number 09/896,692	
FEB	0 4 2004	IN AN APF e several she			Applicant Agrawal		
STEMO	-Sheet	4	OF	2	Filing Date June 29, 2001	Group Art Unit 1635	
	4 TRAUCE	,	"	2	Julie 29, 2001	1000	

		U.	S. Patent Documer	n ts	2000	
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE JP APPROPRIATE
93	4,806,463	05/1986	Goodchild et al.	435	5	
09	5,470,702	01/1993	Hovanessian et al.	435	5/	
	5,591,721	10/1994	Agrawal et al.	514	44	
	5,652,355	07/1997	Metelev et al.	536	24.5	
	5,652,356	07/1997	Agrawal	536	24.5	
	6,608,035	08/2003	Agrawal et al.	51/4	44	
1	6,645,943	11/2003	Agrawal et al.	514	44-	

		Fore	ign Patent Docum	ents			
EXAMINER	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
INITIAL	NUMBER				00000	YES	NO
(15)	WO96/12497	05/02/96	PCT				
7119	WO 98/40058	9/17/1998	PCT				
V 1	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,						

$\overline{}$		Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)						
>)2	A1	Agrawal, et al. (1992) "GEM*91 - An Antisense Oligonucleotide Phosphorothioate as a Therapeutic Agent for AIDS", Antisense Res. Dev. 2:261-266						
0,0	A2	Agrawal et al. (1994) "Potential for HIV-1 Treatment with Antisense Oligonucleotides", J. Biotech. in Healthcare, 1(2):167-182.						
	АЗ	Agrawal, et al. (1995) "Pharmacokinetics of Antisense Oligonucleotides", Clin. Pharmacokinet. 28(1):7-16						
1	A4	Agrawal (1996) "Preface" In Methods in Molecular Medicine: Antisense Therapeutics (Agrawal,ed.) pp. v-vii						
	A5	Agrawal, et al. (1998) "Pharmacokinetics and Bioavallability of Antisense Oligonucleotides Following Oral and Colorectal Administrations in Experimental Animals", in <u>Handbook of Experimental Pharmacology</u> . Vol. 131: Antisense Research and Application, Springer-Verlag, pp. 525-543						
	A6	Agrawal (1999) "Importance of Nucleotide Sequence and Chemical Modifications of Antisense Oligonucleotides," Biochemica et Biophysica Acta 1489:53-68						
A7 Beaucage (1993) "Oligodeoxyribonucleotides Synthesis" In Methods In Molecular Biology, Vol. 20: F Oligonucleotides and Analogs, (Agrawal, ed.) Hurnana Press, Totowa, NJ, pp.33-61								
	A8	Brown (1993) "A Brief History of Oligonucleotide Synthesis" in Methods in Molecular Biology, Vol. 20: Protocols for Oligonucleotides and Analogs, "pp. 1-17						
	A9	Craig et al. (1997) "Patent strategies in the antisense oligonucleotide based therapeutic approach" Exp. Opin. Ther. Patents 7(10):1175-1182						
	A10 Dalabase CAS Registry (2003), (Date of entry: 1997), Registry number 193635-63-1							
	A11	Froehler (1993) "Oligodeoxynucleotide Synthesis," <u>Methods in Molecular Biology, Vol. 20; Protocols for</u> Oligonucleotides and Analogs (Agrawal, ed.) Humana Press, Towtowa, NJ, pp. 63-80						
	A12	Furdon (1989) "RNase II cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds," Nucleic Acids Research, Vol. 17:22, pp. 9193-9205						
7	A13	Galderisi et al. (1999) "Antisense Oligonucleotides as Therapeultic Agents" J. Cell. Physiol. 181:251-257						
EXAM	INER \	DATE CONSIDERED /						
		10/10/04						
		: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation						
if not o	sonfoims	nce and not considered. Include copy with next communication to applicant.						

BOSTON BOSTON 1822760v1

Applicant Agrawal Sheet 2 OF 2 Interview of the State of State o	Subt. Form PTC	1440			Docket Number	Application Number			
Sheet 2 OF 2 June 29, 2001 1635 Sheet 2 OF 2 June 29, 2001 1635 Sheet 2 OF 2 June 29, 2001 1635 And Utsizewicz et al. (1992) "Specific Inhibition of Human Immunodesclency Virus Type 1 Replication by Antisonse Objectureleoides An In Virth Model for Treatment of Human Immunodesclency Virus Type 1 Replication by Antisonse Objectureleoides Phosphorothicates," Proc. Natl. Acad. Sci. USA 89 11209-11213 Lisziewicz et al. (1993) "Antisonse North Model for Treatment of Human Immunodesclency Virus Hotelooide Phosphorothicates," Proc. Natl. Acad. Sci. USA 89 11209-11213 Lisziewicz et al. (1994) "Antisonses Objectureleoides Phosphorothicates," Virus Type 1 In Human Periphate Objectureleoides Phosphorothicates," Proc. Natl. Acad. Sci. USA 89 11209-11213 A15 Cliziewicz et al. (1993) "Antisonses Objectureleoides Phosphorothicates," Proc. Natl. Acad. Sci. USA 89 11209-11213 A16 Replication of Human Immunodesclency Virus Type 1 In Human Periphate Blood Cells," Proc. Natl. Acad. Sci. USA 89 11209-11213 A17 Matheway et al. (1993) "Antisonse Nucleic Acid Theratory of Cancer and AIOS (Wickstorn, ed.), Wiley-Liss, Inc., pp. 159-178 A18 Melley et al. (1993) "FIRLC of Oligodeoxyribonucleoside Phosphorothicates," Abstract No. 1512684, Chemical Abstracts, 128(13):272 A19 Acad Milliagan, et al. (1993) "Translated from Bioorganicheskaya Khriniya 23(9):742-746 A20 Milliagan, et al. (1993) "Current Concepts in Antisanse Dug Designi", Journal of Medicinal Chemistry, 39(14):1923-1937 A21 Milliagan, et al. (1993) "Translated from Bioorganicheskaya Khriniya 23(9):772-766 A22 Milliagan, et al. (1993) "Antisonse Oligonucleosides: A New Therapeutic Principle," Chem. Rev. 90(4):543-583 A23 Tarm, L., et al. (Aug. 2001) "Antisonse Disponucleosides: A New Therapeutic Principle," Chem. Rev. 90(4):543-583 A24 Ulmann et al. (1990) "Antisonse Oligonucleosides: A New Therapeutic Principle," Chem. Rev. 90(4):543-583 A25 Tarm, et al. (1993) "Translated from Bioorganichesides: A New Therapeutic Principle," Chem. Rev. 90(4):543-583 A26 Milliag	SUDI. FORM FIC	J-1445			,				
Applicant Agrawal Applicant Agrawal Applicant Agrawal Applicant Agrawal Filing Date June 29, 2001 Filing Date June 20, 2002 Filing Dat	HEO	RMATION [DISCLO	DSURE					
A14 Clisprovedeoldes: An In Vitro Model for Treatment, Proc. Natl. Acad. Sci. USA 98-11209-11213 A15 Cliponucleoides: An In Vitro Model for Treatment, Proc. Natl. Acad. Sci. USA 98-11209-11213 A15 Clisprovedeoldes: An In Vitro Model for Treatment, Proc. Natl. Acad. Sci. USA 98-11209-11213 A15 Clisprovedeoldes: An In Vitro Model for Treatment Human Immunodeficinory Virus Type 1 Replication of Human Immunodeficinory Virus Type 1 Replication of Human Immunodeficinory Virus Type 1 Replication of Human Immunodeficinory Virus Type 1 In Human Peripheral Blood Cells', Proc. Natl. Acad. Sci. USA 91:7942-7946 A16 Explication of Human Immunodeficinory Virus Type 1 In Human Peripheral Blood Cells', Proc. Natl. Acad. Sci. USA 91:7942-7946 A17 Matsukura et al. (1991) 'A New Concept in AIDS Treatment: An Antisense Approach and its Current Status Toward Clinical Application, 1 Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS (Wickstrom, ed.), Wiley-List, Inc., pp. 159-178 A18 Metelov et al. (1997) FIPC of Oligodeoxynibonucleoside Phosphorothicates', Abstract No. 151268f, Censistry, 23(9):572-746 A20 Miligan, et al. (1997) FiPC of Oligodeoxynibonucleoside Phosphorothicates', Abstract No. 151268f, Censistry, 23(9):742-746 Miligan, et al. (1997) Selecting Effective Antisense Drug Design', Journal of Medicinal Chemistry, 36(14):1923-1921 A21 Miliner et al. (1997) Selecting Effective Antisense Research son Combinatorial Oligonucleotide Arrays', Nature Palu, G., et al. (1998) "In Pursuit of new developments for gene therapy of human diseases, Journal of Bioceptic Milipan, et al. (1998) "In Pursuit of new developments for gene therapy of human diseases, Journal of Medicinal Chemistry, 38(49-496) A22 Palu, G., et al. (1998) "In Pursuit of new developments for gene therapy of human diseases, Journal of Medicinal Chemistry, Journal Chemistry, J						ant			
Liszlewicz et al. (1992) "Specific Inhibition of Human Immunodeficiency Virus Type 1 Replication by Antisense Oligonucleotides: An In Viro Model for Treatment, Proc. Natl. Acad. Sci. USA 89:11209-11213 A15 Liszlewicz et al. (1993) "Long-Term Treatment of Human Immunodeficiency Virus-Infected Cells with Antisense Oligonucleotide Phosphorothioates", Proc. Natl. Acad. Sci. USA 90:3660-3664 Liszlewicz et al. (1994) "Antisense Oligodeoxyrucleotide Phosphorothioate Complementary to Gag mRNA Blocks Reflectation of Human Immunodeficiency Virus Type in Human Peripheral Blood Cells", Proc. Natl. Acad. Sci. USA 91:7494-7466 A16 Replication of Human Immunodeficiency Virus Type in Human Peripheral Blood Cells", Proc. Natl. Acad. Sci. USA 91:7494-7466 A17 Liszlewicz et al. (1991) "A New Concept in AIDS Treatment: An Antisense Approach and its Current Status Toward Clinical Application," in Prospects for Antisense Nucleic Acid Therapy of Cencer and AIDS (Wiley-Liszler, Legal) (1997) "A New Concept in AIDS Treatment: An Antisense Approach and its Current Status Toward Clinical Application," in Prospects for Antisense Rependence Phosphorothicates", Abstract No. 151288, Chemical Materials, 128(1):1272 A17 Metelev, et al. (1998) "Her Col Oligodeoxyribonucleoside Phosphorothicates", Russlan Journal of Bioorganic Acad. A	~(δ /				wal Fox Es			
Lisziewicz et al. (1992) "Specific Inhibition of Human Immunodeficiency Virus Type 1 Replication by Antisense Oligonucleotides: An In Viro Model for Treatment of Human Immunodeficiency Virus-Infected Cells with Antisense Oligonucleotide Phosphorothicates?", Proc. Natl. Acad. Sci. USA 90:3660-3664 A15 Lisziewicz et al. (1994) "Antisense Oligodeoxyrucleotide Phosphorothicate Cells with Antisense Oligodeoxyrucleotide Phosphorothicates", Proc. Natl. Acad. Sci. USA 90:3660-3664 A16 Replication of Human Immunodeficiency Virus Type in Human Peripheral Blood Cells, Proc. Natl. Acad. Sci. USA 91:7942-79466 A17 Lisziewicz et al. (1991) "A New Concept in AIDS Treatment: An Antisense Approach and its Current Status Toward Clinical Application," in Prospects for Antisense Nucleic Acid Therapy of Cencer and AIDS (Wiley-Listien, pp. 199-178) A18 Material et al. (1998) "HPLC of Oligodeoxyribonucleoside Phosphorothicates", Abstract No. 151288, Chemical Acad. Sci. USA 91:784-785. (1997) "HPLC of Oligodeoxyribonucleoside Phosphorothicates", Russian Journal of Bioorganic Acad. Sci. USA 91:794-795. A20 Milligan, et al. (1997) "Selecting Effective Antisense Drug Design", Journal of Medicinal Chemistry, 36(14):1923-1937 A21 Milliner et al. (1997) "Selecting Effective Antisense Progens therapy of human diseases," Journal of Medicinal Chemistry, 36(14):1923-1937 A22 Palus, G. et al. (1999) "In Drustid of new developments for gene therapy of human diseases," Journal of Medicinal Chemistry, 36(14):1923-1937 A23 Tarm. I. et al. (Aug. 2001) "Antisense Oligonucleotides" A New Therapaudic Principie Chem. Rev. 39(1543-564) A24 Uhimann et al. (1997) "Antisense Oligonucleotides" in Methods in Molecular Medicins: Antisense Therapeutic (Agrawalack) Humana Press, Totowa, N. J., p. 1-11 A25 Tarm. I. et al. (Aug. 2007) "Antisense Oligonucleotides" in Methods in Molecular Medicins: Antisense Therapeutic (Agrawalack) "Humana Press, Totowa, N. J., p. 1-11 A26 Phosphorothicate in Rate After Intravenous Administration," Journal of Phosphorothi	0 4 ZDD4	핅		• .	Filing Date	Group Art Und			
A14 Lisztewicz et al. (1992) "Specific Inhibition of Human Immunodeficiency Virus Type 1 Replication by Antisense Oligonucleotides." An In Vitro Model for Treatment", Proc. Natl. Acad. Sci. USA 98:11209-11213 A15 Lisztewicz et al. (1993) "Antisense Oligodoxynucleotide Phosphorothioates", Proc. Natl. Acad. Sci. USA 90:3860-3864 Lisztewicz et al. (1994) "Antisense Oligodoxynucleotide Phosphorothioates" (Proc. Natl. Acad. Sci. USA 90:3860-3864 Lisztewicz et al. (1994) "Antisense Oligodoxynucleotide Phosphorothioate Complementary to Gag mRNA Blocks 91:7942-7946 A16 Explication of Human Immunodeficiency Virus Yppe 1 in Human Peripheral Blood Cells", Proc. Natl. Acad. Sci. USA 91:7942-7946 A17 Lisztewicz et al. (1991) "A New Concept in AIDS Treatment: An Antisense Approach and its Current Status Toward Circinctal Application," in Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS (Wickstrom, ed.), Wiley-List, Inc., pp. 159-178 A18 Meteliev et al. (1995) "PLC of Oligodexynibronucleoside Phosphorothioates", Abstract No. 151268f, Censistry, 23(9):673-677, Transisted from Bioorganic-testsaya (Nimiya 23(9):742-746 A20 Miligan, et al. (1993) "Carrent Concepts in Antisense Drug Design", Journal of Medicinal Chemistry, 36(14):1923-1924 A21 Miliner et al. (1993) "Transisted from Bioorganic-testsaya (Nimiya 23(9):742-746 A22 Palu, c., et al. (1998) "In Dursuit of new developments for gene therapy of human diseases," Journal of Bioorganic Chemistry, 23(9):673-674 A23 Tarmm, I., et al. Aug. 2001 "Antisense Oligonucleotides in Methods in Molecular Medicinal Chemistry, 36(14):1923-1924 A24 Uniman et al. (1995) "Antisense Oligonucleotides in Methods in Molecular Medicinal Chemistry and Company of Antisense Oligonucleotides in Methods in Molecular Medicina, Antisense Tiberspeatif (Aprawal, ed.) Human et al. (1995) "Antisense Oligonucleotides in Methods in Molecular Medicina, Antisense Tiberspeatif (Aprawal, ed.) Human et al. (1995) "Antisense Oligonucleotides in Methods in Methods in Methods in Application of	Sheet A	2	OF	2		1635			
A14 Liszlewicz et al. (1992) "Specific Inhibition of Human Immunodeficiency Virus Type 1 Replication by Antisense Oligonucleolides An In Virto Woole for Trestment, Proc. Natl. Acad. Sci. USA 90:38411299-11219 A15 Liszlewicz et al. (1993) "Long-Term Treatment of Human Immunodeficiency Virus Infected Cells with Antisense Oligonucleolide Phosphoromibiate Complementary to Gag mRNA Blocks Replication of Human Immunodeficiency Virus Type 1 in Human Periphreral Blood Cells", Proc. Natl. Acad. Sci. USA 90:3880-3864 A17 Citical Application," in Prospects for Antisense Approach and Its Current Status Toward Liss, Inc., pp. 159-178 A18 Melieve at al. (1991) "A New Concept in AIDS Treatment: An Antisense Approach and Its Current Status Toward Uss, Inc., pp. 159-178 A18 Melieve at al. (1999) "HPLC of Oligodeoxyribonucleoside Phosphorothicates", Abstract No. 1512681, Chemical Abstracts, 128(13):272 A19 Melieve at al. (1997) "HPLC of Oligodeoxyribonucleoside Phosphorothicates", Abstract No. 1512681, Chemical Abstracts, 128(13):272 A20 Milligan, et al. (1997) "Fluc of Oligodeoxyribonucleoside Phosphorothicates", Abstract No. 1512681, Chemical Abstracts, 128(13):272 A21 Millingan, et al. (1999) "Arrived of the Millingan Control of the Milligan, et al. (1997) "Solecting Effective Antisense Reagonts on Combinatorial Oligonucleotide Arrays," Nature Biotech. 15:537-641 A22 July G., et al. (1999) "Antisense Oligonucleotides" in Melieval Medicinal Chemistry, 36(14):1923-1937 A23 Tarmh, I, et al. (40,9) 2001 "Antisense Oligonucleotides" in Melieval Medicinal Chemistry Abstract (1990) "Antisense Oligonucleotides" in Melieval Medicinal Chemistry Abstract (1990) "Antisense Oligonucleotides" in Melieval Medicinal Chemistry Letters					1				
A15 Liszlewicz et al. (1993) "Antisense Oligodeoxynucleolide Phosphorothioate Complementary to Gag mRNA Blocks Replication of Human Immunodeficiency Virus Type 1 in Human Peripheral Blood Cells", Proc. Natl. Acad. Sci. USA 903860-3884 A16 Replication of Human Immunodeficiency Virus Type 1 in Human Peripheral Blood Cells", Proc. Natl. Acad. Sci. USA 903860-3884 Matsukura et al. (1991) "A New Concept in AIDS Treatment: An Antisense Approach and Its Current Status Toward Cells", Proc. Natl. Acad. Sci. USA 917942-7986 A17 Citical Application," in Prospects for Antisense Nucleic Acid Therapy of Cencer and AIDS (Wickstrom, ed.), Wiley-Uss, Inc., pp. 159-178 A18 Meleve et al. (1993) "TPIC of Oligodeoxyribonucleoside Phosphorothioates", Abstract No. 1512881, Chemical Abstracts, 128(10):272 A19 Melevely et al. (1993) "TPIC of Oligodeoxyribonucleoside Phosphorothioates", Abstract No. 1512881, Chemical Abstracts, 128(10):272 A19 Melevely et al. (1993) "Tell Concepts in Antisense Drug Design", Journal of Medicinal Chemistry, 38(14):1923-1937 A21 Milliar et al. (1993) "Current Concepts in Antisense Reagenis on Combinatorial Oligonucleotide Arrays," Nature Biotechn. 15:537-541 A22 Palu G., et al. (1999) "In Pursuit of new developments for gene therapy of human diseases," Journal of Biotechnology, 68:1-13 A23 Tamm, I., et al. (Aug. 2001) "Antisense Oligonucleotides". New Therapeutic Principle," Chem. Rev. 90(4):543-584 A25 Dang et al. (1996) "History of Antisense Oligonucleotides". New Therapeutic Principle, "Chem. Rev. 90(4):543-584 A26 Dang et al. (1995) "In Work Stability, Disposition and Metabolism of a "Hybrid" Oligonucleotide Phosphorothioate in Rask After Intervenous Administration, Journal of Pharmacock, 1994 and 1994 (1994) "Antisense Oligonucleotides". Bioorganio & Medicinal Chemistry Letters, 10:1051-1054 A27 Phosphorothioate in Rask After Intravenous Administration, Journal of Pharmacock, 1994 and 1994 (1994) "Antisense Oligonucleotides", Bioorganio & Medicinal Chemistry Letters, 10:1051-1054 A28 Disp		Lisziewicz et al. Oligonucleotides	(1992) "Sp :: An <i>In Vi</i>	pecific Inhibition of H	uman Immunodeficiency Virus Type nent", Proc. Natl. Acad. Sci. USA 89:1	1 Replication by Antisense 1209-11213			
A16 Replication of Human immunodeficiency Virus Type 1 in Human Peripheral Blood Cells*, Proc. Natl. Acad. Sci. US. 157942-7986 A17 Matsutura et al. (1991) *A New Concept in AIDS Treatment: An Antisense Approach and Its Current Status Toward Cinical Application,* in Prospects for Antisense Nucleic Acid Therapy of Cencer and AIDS (Wickstrom, ed.), Wiley-Uss, Inc., pp. 159-178 A18 Metielev et al. (1997) *IPIC of Oligodeoxyribonucleoside Phosphorothioates*, Abstract No. 151268f, Chemical Abstracts, 120(13):272 A19 Metielev, et al. (1997) *IPIC of Oligodeoxyribonucleoside Phosphorothioates*, Abstract No. 151268f, Chemical Abstracts, 120(13):272 A20 Milliegr, et al. (1993) *Current Concepts in Antisense Drug Design*, Journal of Medicinal Chemistry, 36(14):1923-1937 A21 Milliner et al. (1993) *Current Concepts in Antisense Drug Design*, Journal of Medicinal Chemistry, 36(14):1923-1937 A22 Milliner et al. (1993) *Current Concepts in Antisense Drug Design*, Journal of Medicinal Chemistry, 36(14):1923-1937 A23 Tarryn, I., et al. (1993) *Toritates therapy in oncology; new hope for an old idea?* The Lancet, 358:489-496 A24 Uhlmann et al. (1990) *Antisense Oligonucleotides* in Methods in Molecular Medicina. Antisense Disponucleotides in Methods in Molecular Medicina. Antisense Disponucleotides and Metabolism of a "Hybrid" Oligonucleotide Phosphorothioate in Rais, *Biochem. Pharmacol. 50(4): 545-556 A27 Zhang et al. (1993) *Pharmacol. 50(4): 545-556 A28 Pichage al. (1993) *Pharmacol. 50(4): 545-556 A29 Zhang et al. (1993) *Pharmacol. 50(4): 545-556 A29 Zhang et al. (1993) *Pharmacol. 50(4): 545-556 A20 Zhang et al. (1993) *Pharmacol. 50(4): 545-556 A21 Zhang et al. (1993) *Pharmacol. 50(4): 545-556 A22 Zhang et al. (1993) *Pharmacol. 50(4): 545-556 A23 Zhang et al. (1993) *Pharmacol. 50(4): 545-556 A24 Zhang et al. (1993) *Pharmacol. 50(4): 545-566 A25 Zhang et al. (1993) *Pharmacol. 50(4): 545-566 A26 Zhang et al. (1993) *Pharmacol. 50(4): 545-566 A27 Zhang et al. (1993) *Pharmacol. 50(4): 545-566 A28	0 A15	Lisziewicz et al. Oligonucieotide	(1993) "Lo Phosphoro	ng-Term Treatment othioates", <i>Proc. Nat</i>	of Human Immunodeficiency Virus-In M. Acad. Sci. USA 90;3860-3864	fected Cells with Antisense			
A17 Clinical Application," in <u>Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS</u> (Wickstrom, ed.), Wiley-Liss, Inc., pp. 159-178 A18 Metelev et al. (1999) "HPLC of Oligodeoxyribonucleoside Phosphorothicates", Abstract No. 151268f, Chemical Abstracts, 128(13):272 A19 Chemistry, 23(9):673-677, Translated from Bioorganicheskaya Khirniya 23(9):742-746 A20 Miligan, et al. (1999) "Fire Concepts in Antisense Drug Design", Journal of Medicinal Chemistry, 36(14):1923-1937 A21 Miliner et al. (1999) "Selecting Effective Antisense Reagens on Combinatorial Oligonucleotide Arrays," Nature Biotech, 15:537-541 A22 Palu, G., et al. (1999) "In Pursuit of new developments for gene therapy of human diseases," Journal of Biotechnology, 68:1-13 A23 Tamm, I., et al. (Aug. 2001) "Antisense therapy in oncology: new hope for an old idea?" The Lancet, 358:489-496. A24 Ulrimann et al. (1990) "Antisense Oligonucleotides: A New Therapeutic Principle," Chem. Rev. 90(4):543-584 A25 Zamecnik (1996) "History of Antisense Oligonucleotides" in Methods in Melocular Medicinae, Antisense Therapeutic Agrawal, ed.), Humana Press, Totowa, NJ, pp. 1-11 A26 Rats, "Biochem. Pharmacol. 50(4): 545-556 A27 Ulriman et al. (1995) "Pharmacokinetics of an Anti-Human Immunodeficiency Virus Antisense Oligonucleotide Phosphorothicate in Rats, "Biochem. Pharmacol. 50(4): 545-556 A27 Dang et al. (1995) "Pharmacokinetics and Tissus Disposition of a Chimetic Oligodeoxynucleotide Phosphorothicate (GEM 91) in HIV-Infected Subjects", Clin. Pharmacol. Ther. 58(1):44-53. A28 Therapeutics 27(2):971-972 A29 Modulated by Modification of a Single Deoxynucleoside", Bioorganic & Medicinal Chemistry Letters, 10:1051-1054 EXAMINER: Infittal it citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation of the Conformance with MPEP § 609: Draw Line through citation of the Conformance with MPEP § 609: Draw Line through citation of the Conformance with MPEP § 609: Draw Line through citation of the Conforman	A16	Replication of Hi 91:7942-7946	uman imm	unodeficiency Virus	Type 1 in Human Peripheral Blood C	ells", Proc. Natl. Acad. Sci. USA			
A18 Matelev et al. (1998) "HPLC of Oligodeoxyribonucleoside Phosphorothicates", Abstract No. 151268I, Chemical Abstracts, 128(13):272 A19 Metelev, et al. (1997) "HPLC of Oligodeoxyribonucleoside Phosphorothicates" Aussian Journal of Bioorganic Chemistry, 23(9):673-677, Translated from Bioorganicheskaya Khimiya 23(9):742-746 A20 Milligan, et al. (1993) "Current Concepts in Antisense Drug Design", Journal of Medicinal Chemistry, 36(14):1923-1937 A21 Milliner et al. (1997) "Selecting Effective Antisense Reagents on Combinatorial Oligonucleotide Arrays," Nature Biotech, 15:537-541 A22 Palu, G., et al. (1999) "In Pursuit of new developments for gene therapy of human diseases," Journal of Biotechnology, 68:1-13 A23 Tamm, I., et al. (Aug. 2001) "Antisense therapy in oncology," new hope for an old idea?" The Lancet, 358:489-496 A24 Uhimann et al. (1990) "Antisense Oligonucleotides: A New Therapeutic Principle," Chem. Rev. 90(4):543-584 A25 Zamecnik (1986) "History of Antisense Oligonucleotides" in Methods in Molecular Medicine. Antisense Therapeutic Agrawal, ed.). Humana Press, Totowa, NJ, pp.1-11 A26 Tams, and al. (1995) "In Vivo Stability, Disposition and Metabolism of a "Hybrid" Oligonucleotide Phophorothicate in Rats., Biochem. Pharmacol Soldy: 545-556 A27 Phosphorothicate (GEM 91) in HIV-Infected Subjects", Clin. Pharmacol. Ther. 58(1):44-53. A28 Tang et al. (1996) "Pharmacokinetics and Tissue Disposition of a Chimeric Oligodeoxynucleoside Phosphorothicate in Rats After Intravenous Administration," Journal of Pharmacology and Experimental Therapeutics 278(2):971-979 DA29 Modulated by Modification of a Single Deoxynucleoside", Bioorganic & Medicinal Chemistry Letters, 10:1051-1054 EXAMINER: Infital if citation is considered, whether or not citation is in conformance with MPEP \$ 609: Draw Line through citation is considered, whether or not citation is in conformance with MPEP \$ 609: Draw Line through citation is conformance.	A17	Clinical Applicati	ion," in <u>Pro</u> 9-178	spects for Antisens	e Nucleic Acid Therapy of Cancer and	1 AIDS (Wickstrom, ed.), Wiley-			
A20 Milligan, et al. (1993) "Current Concepts in Antisense Drug Design", Journal of Medicinal Chemistry, 36(14):1923-1937 A21 Millier et al. (1993) "Selecting Effective Antisense Bragents on Combinatorial Oligonucieotide Arrays," Nature Biotech. 15:537-541 A22 Biotech. 15:537-541 A22 Palu, G., et al. (1999) "In Pursuit of new developments for gene therapy of human diseases," Journal of Biotechnology, 88:1-13 A23 Tarmn, I., et al. (1999) "Antisense Oligonucieotides: A New Therapeutic Principle," Chem. Rev. 39(4):543-584 A24 Uhimann et al. (1990) "Antisense Oligonucieotides: A New Therapeutic Principle," Chem. Rev. 39(4):543-584 A25 Zamenik (1996) "History of Antisense Oligonucieotides: A New Therapeutic Principle," Chem. Rev. 39(4):543-584 A26 Zamenik (1996) "History of Antisense Oligonucieotides: A New Therapeutic Principle," Chem. Rev. 39(4):543-584 A27 Zamenik (1996) "History of Antisense Oligonucieotides: In Methods in Molecular Medicine; Antisense Therapeutic (Agrawal, ed.) Humana Press, Totowa, NJ, pp. 1-11 A28 Zhang et al. (1995) "In Vivo Stability, Disposition and Metabolism of a "Hybrid" Oligonucieotide Phosphorothioate (2EM 91) in HIV -Infected Subjects", Clin. Pharmacol. Ther. 58(1):44-53. A27 Phosphorothioate (2EM 91) in HIV -Infected Subjects", Clin. Pharmacol. Ther. 58(1):44-53. A28 Phosphorothioate in Rata Kar Intravenous Administration, "Journal of Pharmacology and Experimental Therapeutics 278(2):971-979 Zhao, et al. (2000) "immunostimulatory Activity of CpG Containing Phosphorothioate Oligodeoxynucleotide Is Modulated by Modification of a Single Deoxynucleoside", Bioorganic & Medicinal Chemistry Letters, 10:1051-1054 EXAMINEP(Inflital if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation is a conformance with MPEP § 609: Draw Line through citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation is considered, whether or not citation is in conformance with MPEP § 609: Dra	A18	Abstracts, 128(1	3):272						
A21 Milner et al. (1997) "Selecting Effective Antisense Reagents on Combinatorial Oligonucleotide Arrays," Nature Bilotech. 15:537-541 A22 Palu, G., et al. (1999) "In Pursuit of new developments for gene therapy of human diseases," Journal of Bilotechnology, 68:1-13 A23 Tamm, I., et al. (Aug., 2001) "Antisense therapy in oncology: new hope for an old idea?" The Lancet, 358:489-496 A24 Uhlmann et al. (1990) "Antisense Oligonucleotides: A New Therapeutic Principle," Chem. Rev. 90(4):543-584 A25 Zamecnik (1996) "History of Antisense Oligonucleotides" in Methods in Molegular Medicine: Antisense Therapeutic (Agrawal, ed.). Humana Press, Totowa, NJ, pp. 1-11 A26 Zhang et al. (1995) "In Vos Stability, Disposition and Metabolism of a "Hybrid" Oligonucleotide Phosphorothioate in Rats," Biochem. Pharmacol. 50(4): 545-556 A27 Zhang et al. (1995) "Pharmacokinetics of an Antil-Human Immunodeficiency Virus Antisense Oligodeoxynucleotide Phosphorothioate (GEM 91) in HIV-Infected Subjects", Clin. Pharmacol. Ther. 58(1):44-53. A28 Phosphorothioate in Rats After Intravenous Administration," Journal of Pharmacology and Experimental Therapeutics 278(2):971-979 Zhao, et al. (2000) "Immunostimulatory Activity of CpG Containing Phosphorothioate Oligodeoxynucleotide is Modulated by Modification of a Single Deoxynucleoside", Bioorganic & Medicinal Chemistry Letters, 10:1051-1054 EXAMINER: Infitial if cliation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation is in conformance with MPEP § 609: Draw Line through citation.	A19	Chemistry, 23(9)	:673-677.	Translated from Bio	organicheskaya Khimiya 23(9):742-7	46			
A21 Miliner et al. (1997) "Selecting Effective Antisense Reagents on Combinatorial Oligonucleotide Arrays," Nature Biotech 15:597-541 A22 Palu, G., et al. (1999) "in Pursuit of new developments for gene therapy of human diseases," Journal of Biotechnology, 88:1-13 A23 Tamm, I., et al. (Aug. 2001) "Antisense therapy in oncology: new hope for an old idea?" The Lancet, 358:489-496 A24 Uhimann et al. (1990) "Antisense Oligonucleotides: A New Therapeutic Principle," Chem. Rev. 90(4):543-584 A25 Zamecnik (1996) "History of Antisense Oligonucleotides" in Methods in Molecular Medicine: Antisense Therapeutic Agrawal, ed., Humana Press, Totowa, M.J. pp. 1-11 A26 Zamecnik (1995) "In Vivo Stability, Disposition and Metabolism of a "Hybrid" Oligonucleotide Phosphorothioate in Rals." Biochem. Pharmacols. 50(4): 545-556 A27 Zhang et al. (1995) "Pharmacokinetics of an Anti-Human Immunodeficiency Virus Antisense Oligodeoxynucleotide Phosphorothioate in Rals After Intravenous Administration," Journal of Pharmacology and Experimental Therapeutics 278(2):971-979 A29 Zhao, et al. (2000) "immunostimulatory Activity of CpG Containing Phosphorothioate Oligodeoxynucleotide is Modulated by Modification of a Single Deoxynucleoside", Bioorganic & Medicinal Chemistry Letters, 10:1051-1054 EXAMINER: Infitial if cliation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation is in conformance with MPEP § 609: Draw Line through citation.	A20		993) "Curr	rent Concepts in Ant	tisense Drug Design", <i>Journal of Med</i>	icinal Chemistry, 36(14):1923-			
Palu, G., et al. (1999) "In Pursuit of new developments for gene therapy of human diseases," Journal of Biotechnology, 68:1-13 A23 Tarmin, I., et al. (Aug. 2001) "Antisense therapy in oncology: new hope for an old idea?" The Lancet, 358:489-496 A24 Uhlmann et al. (1990) "Antisense Oligonucleotides: A New Therapeutic Principle," Chem. Rev. 90(4):543-584 A25 Zamecnik (1996) "History of Antisense Oligonucleotides" in Methods in Molecular Medicine: Antisense Therapeutic (Agrawal, ed.) Humana Press, Totowa, NJ, pp. 1-11 A26 Rats," Blochem. Pharmacol. 50(4): 545-556 A27 Zhang et al. (1995) "In Vivo Stability, Disposition and Metabolism of a "Hybrid" Oligonucleotide Phosphorothiolate in Rats, "Blochem. Pharmacol. 50(4): 545-556 A27 Zhang et al. (1995) "Pharmacokinetics of an Anti-Human Immunodeficiency Virus Antisense Oligodeoxynucleotide Phosphorothioate in Rats After Intravenous Administration," Journal of Pharmacol. 744-53. Zhang et al. (1995) "Pharmacokinetics and Tissue Disposition of a Chimeric Oligodeoxynucleoside Phosphorothioate in Rats After Intravenous Administration," Journal of Pharmacology and Experimental Therapeutics 278(2):971-979 A29 Zhao, et al. (2000) "Immunostimulatory Activity of CpG Containing Phosphorothioate Oligodeoxynucleotide is Modulated by Modification of a Single Deoxynucleoside", Bioorganic & Medicinal Chemistry Letters, 10:1051-1054 EXAMINER: Initial it clation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation is not conformance with MPEP § 609: Draw Line through citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation is considered.	A21	Milner et al. (199		ing Effective Antiser	nse Reagents on Combinatorial Oligo	nucleotide Arrays," Nature			
A23 Tamm, I., et al. (Aug. 2001) "Antisense therapy in oncology: new hope for an old idea?" The Lancet, 358:489-496 A24 Uhlmann et al. (1990) "Antisense Oligonucleotides: A New Therapeutic Principle," Chem. Rev. 30(4):543-584 A25 Zamecnik (1996) "History of Antisense Oligonucleotides" in Methods in Molecular Medicine; Antisense Therapeutic (Agrawal, ed.) Humana Press, Totowa, NJ, pp. 1-11 A26 Ale (1995) "In Vivo Stability, Disposition and Metabolism of a "Hybrid" Oligonucleotide Phosphorothioate in Rats, Biochem. Pharmacol. 50(4): 545-556 A27 Zhang et al. (1995) "Pharmacokinetics of an Anti-Human Immunodeficiency Virus Antisense Oligodeoxynucleotide Phosphorothioate (Givo Phosphorothioate (Givo Phosphorothioate (Givo Phosphorothioate (Givo Phosphorothioate (Givo Phosphorothioate) (Agrawal, ed.) "Pharmacokinetics and Tissue Disposition of a Chimerto Oligodeoxynucleotide Phosphorothioate (Givo Phosphorothioate (Givo Phosphorothioate (Givo Phosphorothioate (Givo Phosphorothioate (Givo Phosphorothioate) (Agrawal, ed.) "Pharmacokinetics and Tissue Disposition of a Chimerto Oligodeoxynucleoside Phosphorothioate (Givo Phosphorothioate (Givo Phosphorothioate (Givo Phosphorothioate (Givo Phosphorothioate) (Agrawal, ed.) "Pharmacokinetics and Tissue Disposition of a Chimerto Oligodeoxynucleoside is Modulated by Modification of a Single Deoxynucleoside", Bioorganic & Medicinal Chemistry Letters, 10:1051-1054 DATE CONSIDERED LOATE CONSIDE	A22	Palu, G., et al. (* Biotechnology, 6	1999) "In F 38:1-13						
A25 Zamecnik (1995) "History of Antisense Oligonucleotides" in Methods in Molecular Medicine: Antisense Therapeutic (Agrawal,ed.) Humana Press, Totowa, NJ, pp. 1-11 A26 Zhang et al. (1995) "In Vivo Stability, Disposition and Metabolism of a "Hybrid" Oligonucleotide Phosphorothloate in Rats. Biochem. Pharmacol. 50(4): 545-556 A27 Zhang et al. (1995) Pharmacokinetics of an Anti-Human Immunodeficiency Virus Antisense Oligodeoxynucleotide Phosphorothloate (GEM 91) in HIV-infected Subjects", Clin. Pharmacol. Ther. 58(1):44-53. Zhang et al. (1995) "Pharmacokinetics and Tissue Disposition of a Chimeric Oligodeoxynucleoside Phosphorothloate in Rats After Intravenous Administration," Journal of Pharmacology and Experimental Therapeutics 276(2):971-979 Zhao, et al. (2000) "Immunostimulatory Activity of CpG Containing Phosphorothloate Oligodeoxynucleotide is Modulated by Modification of a Single Deoxynucleoside", Bioorganic & Medicinal Chemistry Letters, 10:1051-1054 DATE CONSIDERED LOATE CONSIDERED		Tamm, I., et al.	Aug. 2001) "Antisense therap	y in oncology: new hope for an old id	ea?" The Lancet, 358:489-496			
(Agrawal, ed.) Humana Press, Totowa, NJ, pp. 1-11 A26 A27 Zhang et al. (1995) "In Vivo Stability, Disposition and Metabolism of a "Hybrid" Oligonucleotide Phosphorothioate in Rats, "Blochem. Pharmacol. 50(4): 545-556 A27 Zhang et al. (1995) Pharmacokinetics of an Anti-Human Immunodeficiency Virus Antisense Oligodeoxynucleotide Phosphorothioate (GEM 91) in HIV-Infected Subjects", Clin. Pharmacol. Ther. 58(1):44-53. Zhang et al. (1995) "Pharmacokinetics and Tissue Disposition of a Chimeric Oligodeoxynucleoside Phosphorothioate in Rats After Intravenous Administration," Journal of Pharmacology and Experimental Therapeutics 278(2):971-979 Zhao, et al. (2000) "Immunostimulatory Activity of CpG Containing Phosphorothioate Oligodeoxynucleotide is Modulated by Modification of a Single Deoxynucleoside", Bioorganic & Medicinal Chemistry Letters, 10:1051-1054 BXAMINER DATE CONSIDERED DATE CONSIDERED Lack Considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation is considered.		Uhlmann et al. (1990) "Ant	isense Oligonucleot of Antisense Oligoni	ides: A New Therapeutic Principle," (ucleotides" in Methods in Molecular N	<i>nem. Hev.</i> 90(4):543-584 ledicine: Antisense Thereceutics			
A27 A28 A29 A29 A29 A29 A29 A29 A29		(Agrawal,ed.) Humana Press, Totowa, NJ, pp. 1-11 Zhang et al. (1995) "In Vivo Stability, Disposition and Metabolism of a "Hybrid" Oligonucleotide Phosphorothicate in							
Zhang et al. (1995) "Pharmacokinetics and Tissue Disposition of a Chimeric Oligodeoxynucleoside Phosphorothicate in Rats After Intravenous Administration," Journal of Pharmacology and Experimental Therapeutics 278(2):971-979 A29 Zhao, et al. (2000) "Immunostimulatory Activity of CpG Containing Phosphorothicate Oligodeoxynucleotide is Modulated by Modification of a Single Deoxynucleoside", Bioorganic & Medicinal Chemistry Letters, 10:1051-1054 EXAMINER DATE CONSIDERED DATE CONSIDERED L L L L L L L L L L L L L		Zhang et al. (1995) Pharmacokinetics of an Anti-Human Immunodeficiency Virus Antisense Oligodeoxynucleotide							
Zhao, et al. (2000) "Immunostimulatory Activity of CpG Containing Phosphorothicate Oligodecxynucleotide is Modulated by Modification of a Single Decxynucleoside", Bioorganic & Medicinal Chemistry Letters, 10:1051-1054		Zhang et al. (1996) "Pharmacokinetics and Tissue Disposition of a Chimeric Oligodeoxynucleoside Phosphorothicate in Rats After Intravenous Administration," Journal of Pharmacology and Experimental							
Modulated by Modification of a Single Deoxynucleoside", Bioorganic & Medicinal Chemistry Letters, 10:1051-1054 Date Considered Date C	- 	Therapeutics 27	'8(2):971-9 '0) "Immur	979 Postimulatory Activity	v of CnG Containing Phosphorothips	e Oligodeoxynucleotide is			
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation	A29	Modulated by M	odification	of a Single Deoxyn	ucleoside", <i>Bioorganic & Medicinal C</i>	hemistry Letters, 10:1051-1054			
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation									
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation									
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation									
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation				···					
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation									
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation					WARREN WARREN				
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation									
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation									
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation									
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation									
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation			·						
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation									
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation									
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation	EXAMINER	12-			1	1,104			
CAMMITTED. Injust it chaust is considered, whether of not citation is in contournables with MPEF 3 005. Draw tine bittough classic	EVANINED	V Idition is all the s	e consider	and whether or one		1 -			
if not conformance and not considered. Include copy with next communication to applicant.	if not conform	r. Initial it citation t	s consider idered les	eu, wrietrier or not c dude conv with next	communication to applicant	2 009. DIGH CHA BILDUGH CHADOL			

BOSTON BOSTON 1822760v1